CD133 as a Marker for Cholangiocarcinoma Prognosis
Author Information
Author(s): Fan Linni, He Furong, Liu Hongxiang, Zhu Jin, Liu Yixiong, Yin Zhiyong, Wang Lu, Guo Ying, Wang Zhe, Yan Qingguo, Huang Gaosheng
Primary Institution: State Key Laboratory of Cancer Biology and Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
Hypothesis
The expression of CD133 in human cholangiocarcinoma (CC) is rare and may serve as a prognostic factor for patients.
Conclusion
CD133 expression correlates with the differentiation of cholangiocarcinoma and indicates that it is a potential indicator for differentiation and prognosis.
Supporting Evidence
- CD133 was expressed in all 5 normal liver tissues and 74% of cholangiocarcinoma tissues.
- 90% of well-differentiated cases were CD133 positive.
- CD133 negative expression correlated with poor prognosis in cholangiocarcinoma patients.
Takeaway
This study found that a protein called CD133 can help doctors understand how serious a liver cancer called cholangiocarcinoma is and how well patients might do.
Methodology
Immunohistochemical staining was performed on 59 liver tissue samples, including 54 cholangiocarcinoma specimens and 5 normal liver tissues.
Limitations
The study was limited to a small sample size and specific patient demographics.
Participant Demographics
28 males and 26 females with a mean age of 59.4 years.
Statistical Information
P-Value
P = 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website